Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes

Nuria Morral, Robert McEvoy, Hengjiang Dong, Marcia Meseck, Jennifer Altomonte, Swan Thung, Savio L C Woo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Glucokinase (GK) plays a crucial role in hepatic glucose disposal. Its activity is decreased in patients with maturity-onset diabetes of the young and in some animal models of diabetes. We investigated the feasibility of manipulating GK expression as an adjuvant treatment for type 1 diabetes, using an E1/E3-deleted adenoviral vector (Ad.EF1αGK) delivered to the liver of streptozotocin-induced type 1 diabetic rats. First, we studied the metabolic impact of constitutive glucokinase expression in the absence of insulin. Normal blood glucose levels were observed after gene transfer, and glucose tolerance was substantially enhanced compared with diabetic control animals, suggesting that hepatic GK expression is a feasible mechanism to enhance glucose disposal. In a second study we administered Ad.EF1αGK together with subcutaneous insulin injections to determine whether the combined action of insulin plus GK activity would provide better glucose homeostasis than insulin treatment alone. This combination approach resulted in constant, near-normal glucose values under fed conditions. Furthermore, the animals stayed in the normoglycemic range after an overnight fast, indicating that the risk to develop hypoglycemia is not increased by expression of GK. Alterations of other metabolic routes were observed, suggesting that insulin-regulated expression of GK may be necessary to use the strategy as a treatment of type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1561-1570
Number of pages10
JournalHuman Gene Therapy
Volume13
Issue number13
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Glucokinase
Type 1 Diabetes Mellitus
Adenoviridae
Liver
Insulin
Glucose
Therapeutics
Subcutaneous Injections
Streptozocin
Hypoglycemia
Blood Glucose
Reference Values
Homeostasis
Animal Models

ASJC Scopus subject areas

  • Genetics

Cite this

Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes. / Morral, Nuria; McEvoy, Robert; Dong, Hengjiang; Meseck, Marcia; Altomonte, Jennifer; Thung, Swan; Woo, Savio L C.

In: Human Gene Therapy, Vol. 13, No. 13, 2002, p. 1561-1570.

Research output: Contribution to journalArticle

Morral, Nuria ; McEvoy, Robert ; Dong, Hengjiang ; Meseck, Marcia ; Altomonte, Jennifer ; Thung, Swan ; Woo, Savio L C. / Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes. In: Human Gene Therapy. 2002 ; Vol. 13, No. 13. pp. 1561-1570.
@article{2886fe74f93d47769892bf804f982638,
title = "Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes",
abstract = "Glucokinase (GK) plays a crucial role in hepatic glucose disposal. Its activity is decreased in patients with maturity-onset diabetes of the young and in some animal models of diabetes. We investigated the feasibility of manipulating GK expression as an adjuvant treatment for type 1 diabetes, using an E1/E3-deleted adenoviral vector (Ad.EF1αGK) delivered to the liver of streptozotocin-induced type 1 diabetic rats. First, we studied the metabolic impact of constitutive glucokinase expression in the absence of insulin. Normal blood glucose levels were observed after gene transfer, and glucose tolerance was substantially enhanced compared with diabetic control animals, suggesting that hepatic GK expression is a feasible mechanism to enhance glucose disposal. In a second study we administered Ad.EF1αGK together with subcutaneous insulin injections to determine whether the combined action of insulin plus GK activity would provide better glucose homeostasis than insulin treatment alone. This combination approach resulted in constant, near-normal glucose values under fed conditions. Furthermore, the animals stayed in the normoglycemic range after an overnight fast, indicating that the risk to develop hypoglycemia is not increased by expression of GK. Alterations of other metabolic routes were observed, suggesting that insulin-regulated expression of GK may be necessary to use the strategy as a treatment of type 1 diabetes.",
author = "Nuria Morral and Robert McEvoy and Hengjiang Dong and Marcia Meseck and Jennifer Altomonte and Swan Thung and Woo, {Savio L C}",
year = "2002",
doi = "10.1089/10430340260201653",
language = "English (US)",
volume = "13",
pages = "1561--1570",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "13",

}

TY - JOUR

T1 - Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes

AU - Morral, Nuria

AU - McEvoy, Robert

AU - Dong, Hengjiang

AU - Meseck, Marcia

AU - Altomonte, Jennifer

AU - Thung, Swan

AU - Woo, Savio L C

PY - 2002

Y1 - 2002

N2 - Glucokinase (GK) plays a crucial role in hepatic glucose disposal. Its activity is decreased in patients with maturity-onset diabetes of the young and in some animal models of diabetes. We investigated the feasibility of manipulating GK expression as an adjuvant treatment for type 1 diabetes, using an E1/E3-deleted adenoviral vector (Ad.EF1αGK) delivered to the liver of streptozotocin-induced type 1 diabetic rats. First, we studied the metabolic impact of constitutive glucokinase expression in the absence of insulin. Normal blood glucose levels were observed after gene transfer, and glucose tolerance was substantially enhanced compared with diabetic control animals, suggesting that hepatic GK expression is a feasible mechanism to enhance glucose disposal. In a second study we administered Ad.EF1αGK together with subcutaneous insulin injections to determine whether the combined action of insulin plus GK activity would provide better glucose homeostasis than insulin treatment alone. This combination approach resulted in constant, near-normal glucose values under fed conditions. Furthermore, the animals stayed in the normoglycemic range after an overnight fast, indicating that the risk to develop hypoglycemia is not increased by expression of GK. Alterations of other metabolic routes were observed, suggesting that insulin-regulated expression of GK may be necessary to use the strategy as a treatment of type 1 diabetes.

AB - Glucokinase (GK) plays a crucial role in hepatic glucose disposal. Its activity is decreased in patients with maturity-onset diabetes of the young and in some animal models of diabetes. We investigated the feasibility of manipulating GK expression as an adjuvant treatment for type 1 diabetes, using an E1/E3-deleted adenoviral vector (Ad.EF1αGK) delivered to the liver of streptozotocin-induced type 1 diabetic rats. First, we studied the metabolic impact of constitutive glucokinase expression in the absence of insulin. Normal blood glucose levels were observed after gene transfer, and glucose tolerance was substantially enhanced compared with diabetic control animals, suggesting that hepatic GK expression is a feasible mechanism to enhance glucose disposal. In a second study we administered Ad.EF1αGK together with subcutaneous insulin injections to determine whether the combined action of insulin plus GK activity would provide better glucose homeostasis than insulin treatment alone. This combination approach resulted in constant, near-normal glucose values under fed conditions. Furthermore, the animals stayed in the normoglycemic range after an overnight fast, indicating that the risk to develop hypoglycemia is not increased by expression of GK. Alterations of other metabolic routes were observed, suggesting that insulin-regulated expression of GK may be necessary to use the strategy as a treatment of type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0036377928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036377928&partnerID=8YFLogxK

U2 - 10.1089/10430340260201653

DO - 10.1089/10430340260201653

M3 - Article

C2 - 12228011

AN - SCOPUS:0036377928

VL - 13

SP - 1561

EP - 1570

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 13

ER -